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Quantitative evidence synthesis through meta-analysis is central to
evidence-based medicine. For well-documented reasons, the meta-analysis
of individual patient data is held in higher regard than aggregate data. With
access to individual patient data, the analysis is not restricted to a “two-stage”
approach (combining estimates and standard errors) but can estimate parame-
ters of interest by fitting a single model to all of the data, a so-called “one-stage”
analysis. There has been debate about the merits of one- and two-stage analysis.
Arguments for one-stage analysis have typically noted that a wider range of
models can be fitted and overall estimates may be more precise. The two-stage
side has emphasised that the models that can be fitted in two stages are suf-
ficient to answer the relevant questions, with less scope for mistakes because
there are fewer modelling choices to be made in the two-stage approach. For
Gaussian data, we consider the statistical arguments for flexibility and precision
in small-sample settings. Regarding flexibility, several of the models that can
be fitted only in one stage may not be of serious interest to most meta-analysis
practitioners. Regarding precision, we consider fixed- and random-effects
meta-analysis and see that, for a model making certain assumptions, the
number of stages used to fit this model is irrelevant; the precision will be
approximately equal. Meta-analysts should choose modelling assumptions
carefully. Sometimes relevant models can only be fitted in one stage. Otherwise,
meta-analysts are free to use whichever procedure is most convenient to fit the
identified model.
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1 INTRODUCTION
Quantitative synthesis of evidence frommultiple studies throughmeta-analysis is a cornerstone ofmedical, psychological,
and social research. Historically, parameter estimation in meta-analysis has involved two stages, taking (published) esti-
mates of effect and standard errors from each study (first stage), then combining them (second stage), assigning weights
to each study, with weights most often based on the inverse variance.
Over the last 2 decades, the bar for high-quality systematic reviews has been raised, particularly by reviewers who have
collected participant-level data for included studies and analysed these datasets to obtain their own trial-level estimates
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in place of published estimates. The merits of using individual participant data (IPD) are well documented1-4: Data can
be checked by the reviewer; consistent inclusion and exclusion criteria can be applied; participants can be included who
were not in the original reports; longer follow-up may be included than at the time of the primary study report; analyses
can be executed identically for each study, meaning that it is more reasonable to combine estimates; and there is greater
scope to investigate interactions. Collecting and checking IPD is a time-consuming, diplomatic, and expensive exercise,
so when IPD has been obtained, the advantages should be fully leveraged.
When IPD have been obtained, the analysis is not restricted to combining estimates and standard errors from published
data. Instead, the whole analysis can be done in one stage. Themerits of “one-stage” compared to “two-stage” approaches
have been debated.5-8 Those who argue for one-stage methods tend to be statistically trained, while those who argue for
two-stage methods are typically meta-analysts whose primary training is not statistical. (Executing a thorough systematic
review and IPD meta-analysis involves many non-statistical skills.) There seems to be support for both perspectives.
The views of a one-stage exponent are exemplified by an anonymous reviewer of one of the authors' (DJF) work on a
Stata package to perform two-stage meta-analysis of IPD.3 The reviewer was ambivalent. Despite approving the package,
he or she was convinced that two-stage methods have little to offer, writing
The debate is ongoing but the statistical merits of one-stage IPD far outweigh the benefits of a two-stage
approach …
… the merit of the one-stage is doing an analysis that is definitely more accurate …
… a simulation study is needed to quantify how much better one-stage is in certain scenarios …
I do not think it [two-stage meta-analysis] should be recommended for use when a one-stage approach is
possible . . . .
These opinions were apparently informed byMathew and Nordström's paper,6 which shows that a two-stage procedure
can be at best as asymptotically efficient as a one-stage procedure. This is in contrast to the view of Burke et al who argue
that “differences arise because of differentmodelling assumptions, rather than the choice of one-stage or two-stage itself.”9
The two-stage perspective tends to be that the models and their assumptions are transparent and of scientific value and
are sufficient to address relevant substantive questions. There is arguably less transparency in the reporting of models
used with one-stage analysis, as evidenced by two recent reviews.10,11 Simmonds et al found that “One-stage methods
were in general more poorly described, perhaps because of the greater complexity involved in describing properties of
regression models.”10 The main choices for two-stage analysis are around whether to model treatment effects as fixed or
random and (a closely related choice) how much weight studies should contribute to the overall estimate. The apparent
simplicity of two-stage analysis, combined with the longer history of two-stage estimation in the context of meta-analysis,
may be why descriptions tend to be better.
The aim of this paper is to consider the statistical arguments for one- and two-stage analysis in the context of Gaussian
outcome data, and particularly to identify differences in precision for models that can be fitted in either way. This is
done in the finite-sample setting; the reality we all work in. That is, our results allow explicitly for small numbers of
patients-per-study and the implied uncertainty about study-specific estimates.
To aid clarity, we focus here on the simple setting where the IPD include a quantitative outcome, an indicator of treat-
ment assignment, a participant identifier, and a study identifier. It is assumed that the focus of the meta-analysis is on the
treatment effect and that no covariates are present. This is an inadequate summary of a meta-analysis,12 but this is often
the primary focus and permits a clear discussion of the arguments for and against one- and two-stage approaches.
As evidenced by the above quotes, two-stage procedures can receive a bad press from statisticians, and we seek to
establish the extent to which such comments are justified, not asymptotically, but in practice.
2 MODELS FOR META-ANALYSIS
Even for the relatively simple structure of datasets considered here, there are several possible models for performing a
meta-analysis. Borrowing heavily from Senn,13 Table 1 lists seven that might be of interest. We define our notation below
before discussing the models in Table 1.
2.1 Notation
Let y denote outcome and x denote treatment assignment14 (coded −0.5/+0.5). Let i = 1, … , I index studies and j =
1, … ,ni index patients within a study, so that yij is the outcome for the jth patient in the ith study. Let 𝛼 be the intercept
term and 𝛽 be the treatment effect, the parameter of central interest. The interpretation of 𝛼 and 𝛽 will depend on which
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4 MORRIS ET AL.
model is used; for example, in model I, 𝛼 represents mean outcome (because treatment is coded −0.5/+0.5 and it is
assumed that randomisation is 1:1).
There are 3 possibilities for modelling the main effect (intercept) of study:
𝛼i = 𝛼,∀i a single constant; studies share an intercept
𝛼i = 𝛼 + ai fixed-study intercept
𝛼i = 𝛼 + aiwhereai ∼ N(0, 𝜆2) random-study intercept
Similarly, for the treatment effect,
𝛽 i = 𝛽,∀i common treatment effect (no interaction)
𝛽 i = 𝛽 + bi fixed treatment effects which are different for each study
(fixed treatment-by-study interaction terms)
𝛽 i = 𝛽 + bi where bi ∼ N(0, 𝜏2) random treatment effect
(random treatment-by-study interaction)
Let 𝜀i𝑗 ∼ N(0, 𝜎2i ). With a one-stage analysis, 𝜎
2
i can be allowed to vary by study or restricted such that 𝜎
2
i = 𝜎
2∀i or
some combination of these. For example, a fixed-effects model based on ordinary least squares (OLS) implies 𝛼i = 𝛼 + ai
(with ai representing fixed differences in intercepts for i = 1, … ,), 𝛽 i = 𝛽, and 𝜎2i = 𝜎
2. Two-stage analysis by default
allows 𝜎2i to vary by i (we have referred to this as default because, at the time of writing, we believe all software packages
which perform stage two do so under this assumption). However, the assumption that 𝜎2i = 𝜎
2 can also be invoked with a
two-stage analysis (see Olkin and Sampson5). To do this, relative study weights are proportional to a function of ni rather
than of ?̂?2i . Weighting in this way exactly recovers the one-stage OLS estimate.
15 We return to this point later.
Wedistinguish here between two types of variancewewill refer to, particularly for understanding theworkings provided
in the appendices.We denote the true variance of the estimator of 𝛽 by Var(𝛽). In the frequentist sense, this is the long-run
variance of 𝛽 under repeated sampling. Second, the estimated variance is denoted by V̂ar(𝛽). This is what is estimated in
a specific realisation of a meta-analysis. A good variance estimator should have expectation Var(𝛽).
2.2 Flexibility and estimands
Note the column of Table 1 stating whether the model can be fitted in one stage (top) or two (bottom). Of the models
considered, (I), (III), and (IV) cannot be fitted in two stages. Further, although model (VI) can be fitted in two stages, it
does not provide an estimate of 𝛽. This restriction is what is meant when one-stage approaches are promoted for their
flexibility.
Note that, provided that the available evidence is representative and the model specific assumptions hold, any of the
models listed in Table 1 could provide an unbiased estimate of the treatment effect and its variance. The practical settings
for which this is truemay be rather limited. For example, if each study used simple randomisation and the same allocation
ratio (not necessarily 1:1), then 𝛽 would be unbiased for all themodels in Table 1. The interesting point is that this depends
only on the design of the included studies and not on the true data-generatingmodel.We refer interested readers to Parzen
et al16 or Kahan and Morris.17
3 A COMPARISON OF ONE- AND TWO-STAGE APPROACHES FOR LINEAR
MODELS
3.1 Fixed-effects model (model II)
We wish to compare the variance of one- and two-stage fixed-effect meta-analysis. There are 2 approaches to this.
1. Compare the variance of “default” or most natural one- and two-stage fixed-effect estimators.
2. Compare the variance of one- and two-stage estimators when the models and associated assumptions are the same.
The former is an apples-vs-oranges comparison. It is interesting because one-stage fixed-effect estimators are most nat-
urally estimated by OLS (this is the default in all major software), which assumes a common variance across studies
(previously described as “scarcely credible” in the context of meta-analysis).15 Meanwhile the two-stage inverse-variance
estimatormost naturally assumes heterogeneity of variances across studies (again this is the default in software). Assump-
tions about within-study variances impact on the relative weights of studies and thus on the overall estimate of 𝛽 and
its variance. Results may differ between one- and two-stage analysis due to subtle differences in modelling assumptions,
such as this one. It is important not to attribute this to the number of stages in computation. Therefore, the comparison
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of defaults is very much a comparison of the modelling assumptions, rather than of the procedure by which the models
are estimated (ie, in one or two stages).
The most natural one-stage analysis is to fit a model based on OLS, where the theory is well understood. This assumes
𝜎2i is common across studies. The theory is less well understood when 𝜎
2
i are allowed to be study specific, and the model
is estimated based on variance-weighted least squares. The fact that the mixed command is needed to fit this model
demonstrates that it is not a natural one-stage model to fit. We derive the one-stage estimator of 𝛽 and variance estimator
allowing study-specific 𝜎2i in Appendix A.1. These turn out to be the same as the two-stage inverse-variance estimator
and the usual asymptotic inverse-variance formula:
V̂ar(𝛽) =
I∑
i=1
4?̂?2i
ni
. (1)
For details, see Appendix A.1.
Thus, when we allow study-specific variances, computing our estimates in one or two stages would lead to identical
point estimates and variance estimates. (In fact, the variance estimators are biased downwards in finite samples because
they assume that the ?̂?2i are known rather than estimated, as is assumed inMathew andNordström.
6) This result is related
to the result of Olkin and Sampson,5 when both models impose a shared 𝜎2i , and to Lunn et al,
18 who present a two-stage
strategy for fitting a full Bayesian model.
We focus on comparisons of variance here and, to do so, needed to derive some new theoretical results. Appendix A
works through themathematics, while the rationale and results are given here. The overall aim is to calculate the expected
value of the variance for the OLS and inverse-variance estimators. This involved:
1. Calculation of the expected value of the asymptotic variance formula (1) for the inverse-variance estimator (noting
again that this variance estimator is biased downwards in small samples and so produces misleading conclusions)
(Appendix A.2).
2. Derivation of a new variance formula which explicitly acknowledges that the ?̂?2i are estimates and so is unbiased
with practical sample sizes (Appendix A.3). This tends to the standard formula (1) as all ni → ∞ but is less biased
when any ni is small. This is
Var(𝛽) ≃ 1
Ŵ
+
I∑
i=1
2𝜎4i
ni − 1
(
𝛽i − 𝛽
Ŵ
)2
, (2)
where 1∕Ŵ is the standard inverse-variance formula (1).
3. Calculation of the expectation of the new small-sample variance formula (2) (Appendix A.4).
The expected value of the asymptotic and small-sample variance formulas are then compared with the version that
assumes common ?̂?2i .
Results are shown in Figure 1, showing very little effect of the number of studies I (the 40 translucent curves are almost
on top of each other) but some effect of the number of patients per study ni. However, this effect becomes small withmore
than about 25 patients per study. This is shown for scenarios where all studies contain the same number of participants
but could equally be done with specific incidences of unbalanced data.
This demonstrates that assuming 𝜎2i is the same across studies reduces variance of 𝛽 when ni is small. This being the
assumption underlying OLS, it is typically associated with one-stage analysis. Two-stage fixed-effects meta-analysis typi-
cally allows 𝜎2i to be study specific. These aremerely defaults, and it is not necessary for either procedure to use the default
assumption.
3.2 Random-effects model (model V)
Here, we consider model V of Table 1, often designated as “random-effects” meta-analysis, because the I treatment effects
are assumed to follow a probability distribution. There is a bewildering range of competing two-stage estimators for this
model.3
We will consider the restricted maximum likelihood estimator. It is attractive because it is more efficient than
moment-based estimators such as DerSimonian and Laird's method but can provide consistent estimates of variance
parameters. For finite-sample inference with restricted maximum likelihood (REML) estimation, Kenward and Roger's
approximate correction to the covariance matrix and degrees of freedom is the best available option.19
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FIGURE 1 Ratio of two- to one-stage expected value of variances, using the asymptotic variance formula (1) (lines below 1) and the small
sample formula (2) (lines above 1). The plot shows 39 translucent lines as the number of studies increases from i = 2, … , 40. The lines for
smaller i are higher for both panels, but differences are negligible
It is possible to fit the random-effects meta-analysis REML realisation of the Kenward–Roger correction in one stage via
mixed in Stata or proc mixed in SAS. The covariance and degrees of freedom for two-stage meta-analysis of a single
parameter has not previously been derived; we provide the derivation in Appendix B.
The one- and two-stage versions of these models were compared in a simulation study. The simulation design follows.
This is structured as aims, data-generating mechanism, methods, estimand, and performance measures.
• Aims
The aim of the simulation study is to compare one- and two-stage procedures in terms of (1) precision of meta-analysis
with random treatment effects and fixed-study intercepts and (2) coverage of 95% confidence intervals. Both are with
respect to 𝛽, the overall average treatment effect.
• Data-generating mechanism
Individual participant data were simulated for independently 2 up to 40 studies from model V of Table 1, that is,
studies had fixed intercepts and random treatment effects (drawn from a Gaussian distribution). One thousand sim-
ulated datasets were produced using Stata 14's default random-number generator (64-bit Mersenne twister). For the
data-generating mechanism we used, parameter values were set to 𝛼 = ai = 0∀i, 𝛽 = 0 with E[𝜏2] = 1, and E[?̂?2] = 1
with Var(?̂?2) = 50∕𝜒250 (where 𝜒250 denotes a random draw from a 𝜒2 distribution on 50 df). Study sizes were unbal-
anced. Following Rücker et al,20 based on Galandi et al,21 study sizes ni were drawn from a log-normal distribution with
E(logni) = 3.798 and SD(logni) = 1.104, with ni rounded to the nearest integer or to 20 for any drawn values < 20.
• Methods
One-stage analysis was done in SAS 9.3 using proc mixed, while two-stage analysis3 used ipdmetan in Stata 14,
based on the same simulated datasets. The choice of SAS for one-stage models was for computational speed: Both
packages return the same results, but SAS currently gets there faster. The only difference in the methods is that the
two-stage variance estimates were based on expected information and the one-stage on observed.
• Estimand
The estimand of interest is the meta-analytic estimate of average overall treatment effect 𝛽. As earlier mentioned, we
acknowledge that this is not an adequate summary of a meta-analysis but is usually the parameter of central interest.
• Performance measures
The key performance measure is precision: the inverse of the empirical variance of 𝛽.22 This is estimated for two-stage
relative to one-stage (see White22) and presented as “% gain”. The empirical variance is based only on the REML point
estimate and so does not depend on the Kenward–Roger adjustment. To assess the new variance and df adjustments,
we also compare the coverage of nominal 95% confidence intervals.
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FIGURE 2 Simulation study results from 1000 repetitions plotted for 2 up to 40 studies in a meta-analysis. Upper panel: relative % increase
in precision for two- vs one-stage restricted maximum likelihood estimation. Lower panel: coverage of Kenward–Roger confidence intervals
The Stata files required to generate data and run one- and two-stage analyses are included as a supplement to this
article. Also included is the simulation analysis of the results (though the code to produce figures is not).22
Figure 2 plots results for relative precision and coverage. All results are accompanied by 95% Monte Carlo confidence
intervals to describe simulation uncertainty.22
The upper panel displays relative precision, showing that the two-stage REML estimator has precision extremely similar
to its one-stage counterpart under this data-generating mechanism. Although we are not able to obtain an analytic result
to support whether this is a general or specific result, it appears to be in line with the equivalence of one- and two-stage
for fixed-effects meta-analysis when the same models are fitted.
Coverage results (the lower panel of Figure 2) indicate that both methods tend to have good coverage, except when the
number of studies is below 5. Inspection of the simulation results shows that variance estimates are accurate, on average
very close to the true (empirical) variance. The conservative intervals appear to be due to the df estimated by two-stage
Kenward–Roger approach being conservative (two-stage) and anti-conservative (one-stage). For both procedures, the vari-
ance formulas closely matched the empirical variance of the REML estimate of 𝛽. The issue with confidence interval
coverage is then due to the df used. A comparison of the one- and two-stage df across simulation runs showed that the
one-stage df were slightly higher than the two-stage counterpart. This is apparently due to the approximations involved
in the Taylor expansions, which begin to fail in different directions at very small study sample sizes.
4 ILLUSTRATION OF METHODS FOR INDANAMETA-ANALYSIS
The Indana data includes IPD from 10 trials of antihypertensive drugs in patients at high risk of cardiovascular
disease.23,24 Several outcome variables were collected, such as death, stroke, systolic blood pressure, diastolic blood
pressure, and cholesterol. We focus here on systolic blood pressure (SBP), which was recorded annually at years 1 to 5 in
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STOP
SHEP
MRC2
MRC1
EWPH
COOP
ANBP
Study
-20.98 (-22.91, -19.05)
-13.93 (-14.92, -12.94)
-15.96 (-17.02, -14.89)
-10.60 (-11.13, -10.08)
-21.25 (-24.29, -18.22)
-14.75 (-17.81, -11.69)
-9.74 (-10.89, -8.59)
Effect (95% CI)
1539
4243
4119
16361
705
794
3439
n
-25 -20 -15 -10
FIGURE 3 Forest plot of mean difference in systolic blood pressure at 1 year by randomised arm, for 7 trials in the indana data. The size
of squares is based on fixed-effect weights with study-specific 𝜎2i . CI, confidence interval
TABLE 2 Results from meta-analysis of INDANA data: overall mean difference in systolic blood
pressure under different meta-analysis models
M-Amodel Estimation procedure ?̂? (95% CI), mmHg
Fixed effect, shared 𝜎2i One-stage −12.5254 (−12.9128, −12.1382)
Two-stage −12.5255 (−12.9112, −12.1398)
Fixed effect, study-specific 𝜎2i One-stage
a −12.3404 (−12.7236, −11.9571)
Two-stagea −12.3404 (−12.7236, −11.9571)
Random effects, study-specific 𝜎2i One-stage −15.2069 (−19.3984, −11.0153)
(REML with Kenward–Roger adjustment) Two-stage −15.2068 (−18.5534, −11.8602)
aConfidence intervals (CIs) computed using asymptotic variance formula (1).
seven of the 10 studies and never in the remaining three. As previously, we consider a simple analysis involving a linear
regression of SBP on randomised group. Analysis was restricted to participants with observed values of SBP at 1 year.
The situation is shown in Figure 3, a forest plot of the within-study estimates of the mean difference in SBP at 1 year.
The trials are highly heterogeneous in many ways, and this is apparent in the estimated treatment effects. A fixed-effect
meta-analysis will thus produce a confidence interval that is too narrow and relates to what is arguably an ill-defined
target parameter, as the assumption of a constant treatment effect is clearly not supported. Meanwhile, the smaller trials
seem to have larger effects, so that the random-effects point estimate may be too large. Our purpose here is not to produce
the most appropriate summary of the overall effect in terms of the point estimate and confidence interval; instead, we
aim to demonstrate the impact of different modelling assumptions and of the number of stages used to fit a given model,
on these quantities.
We consider three different modelling assumptions, matching the models considered in Section 2. First, a fixed-effect
meta-analysis where 𝜎2i is assumed to be equal in all studies; second, a fixed-effect meta-analysis under the assumption
that 𝜎2i are different across studies; and third, a random-effects meta-analysis also allowing 𝜎
2
i to vary across studies.
Table 2 gives the results of applying one- and two-stage procedures for parameter estimation. Results are intentionally
given to 4 decimal places. We see clear differences between different modelling assumptions, the largest difference being
between the fixed- and random-effects models. However, the different procedures produce almost identical estimates of
𝛽 and very similar confidence intervals.
5 DISCUSSION
Focusing on practical sample sizes (rather than asymptotic results), this paper attempts to resolve the debate about using
one- or two-stage estimation methods in meta-analysis. We have considered Gaussian data and demonstrated theoreti-
cally (for fixed effect) and via simulation (for random-effects models), that provided the same underlying model is used,
inference from one- and two-stage procedures is practically equivalent for 2 models which are practically relevant.
To make progress, we focused on a very simple data structure and considered combining evidence from randomised
studies. We considered the main arguments regarding “flexibility” and precision. Table 1 shows that a wider range of
statistical models can be fitted in a one-stage framework; however, for many meta-analyses, this flexibility is not needed.
To study precision, we derived some new results. Specifically, the one-stage fixed-effects estimator of 𝛽 which allows
for study-specific variances; a new variance estimator which admits that ?̂?2i are estimated and not known (again for the
fixed-effect model allowing study-specific variances); and estimated the expectation of this formula, comparing it to the
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expectation of the OLS variance, where ?̂?2i is assumed to be equal across all studies. For random-effect meta-analysis, we
also calculated and implemented the Kenward–Roger small sample correction.
In practical sample sizes, our work shows that the arguments regarding precision are largely redundant, as previ-
ously shown asymptotically for more general models.7 Mathew and Nördstrom claim to show that a one-stage analysis
will always be at least as precise as two-stage, but the only example of an inequality is for a meta-analysis with no
study effects at all, which is of no practical interest.6 Appendix A.1 shows that the fixed-effect model can be fitted using
weighted one-stage estimation,which returns the same estimates aswould be obtained through inverse-varianceweighted
two-stage estimation. Meanwhile, Senn15 shows how OLS estimates can be recovered from summary data in two stages.
The results displayed in Figure 1 show that the latter is more precise than the former. Thus, analysis in two stages may
be less precise, more precise, or identical to two stages, depending on the modelling assumptions made by the computa-
tional procedure. In summary, these papers do not contradict our key finding, which is that for equivalent models, fitting
by a one- or two-stage procedure gives practically equivalent results.
Improvements in precision must be attributed to different modelling assumptions, that is, the precision argument for
one-stage procedures is actually about flexibility again. A different model may be more or less precise: In general, we buy
information with assumptions. We argue that model choice should never be based on precision. Opting to fit a model
in one stage or two based on the perceived efficiency is in fact doing exactly this. In practice, it is important to make
modelling assumptions that are tenable and fit the model as using whatever procedure allows for these assumptions. For
the assumptions which may change between one- and two-stage procedures, see Burke et al.9
Due to the simple data structure considered, we have not touched on covariate adjustment here. Adjusting for the main
effects of covariates may be desirable, either to obtain a valid estimate of Var(𝛽i) (for example, where covariates have been
balanced by design25) or to increase power.26 Here, a one-stagemodel can estimate covariate effects to have the same values
across all studies. Two-stage analysis relaxes this assumption by fitting a model which implies separate covariate effects
for each study, which we conjecture is the correct way to ensure a valid estimate of Var(𝛽i). To fit a one-stage version of
this model, covariate–study interaction terms need to be included and, if the modelling assumptions are identical, our
results would hold. If the covariate effects truly differ by study, then the model that incorporates this (whether fitted by a
one- or two-stage procedure) will tend to give more precise estimates; the converse is also true.
For meta-analysis of patient-level treatment−covariate interactions, using the two-stage procedure of fitting a model
including interactions and combining these within-study interactions in a second-stage meta-analysis, guards against
ecological bias.27-29 As always, a practically equivalent model can be fitted using a one-stage procedure; however, in this
setting, care needs to be taken over the parameterisation and study-specific covariate means must be adjusted for.28,29
This may not be intuitive, and in this context, a one-stage analysis should aim to estimate the same effect as a two-stage
analysis. Here, a model that can be fitted in one stage but not two may actually be misleading (“deluded” in the parlance
of Fisher et al).28
For practicalmeta-analysis, a clear description of themodel and assumptions is important. See Burke et al9 for a descrip-
tion of practical assumptions which may differ between one- and two-stage meta-analysis: The relevance of each of these
should be considered and described.
When fitting a model in two stages, it is important to describe whether a fixed- or random-effects model is being used.
For fixed-effectmodels, the assumption about commonor study-specific ?̂?2i thenneeds to be described. For randomeffects,
the random-effects model should be described. The clearest way of doing this is in terms of the estimator of tau squared
(eg, DerSimonian–Laird or REML3) followed by any additional details such as use of theHartung–Knapp/Sidik–Jonkman
or Kenward–Roger variance correction.
When fitting a model in one stage, some modelling aspects to describe may be whether random effects were estimated
and the parameters they were attached to; whether ?̂?2i was shared or study specific; any correction to the covariance
matrix; whether parameters for covariate effects were constrained to be equal or allowed to vary across studies; and how
interactions were estimated.
We encourage those involved inmeta-analysis methodology to focusmore on consideration of models and assumptions
and less on the procedures used for parameter estimation. The procedure used (one or two stages) is a computational
tool; the model being fitted is what the tool aims to construct, and a tool that does the required job conveniently should
be favoured.
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APPENDIX A: PROPERTIES OF WEIGHTED ESTIMATORS
The below sections derive the variance of the fixed-effects inverse-variance estimator. Unless otherwise stated, summa-
tions are over all i, the study index.
A.1 Variance estimator for a one-stage analysis assuming varying variances
The fixed effects model is Yij = 𝛼i + 𝛽Xij + 𝜀ij, where 𝜀ij ∼ N(0, 𝜎2), i indexes studies and j indexes patients. This model is
estimated by (X′X)−1X′Y and covariance matrix by (X ′X)−1?̂?2. We require the expectation of V̂ar(𝛽).
Assume that we have I studies, each with ni patients. Define the
∑ni × (I + 1) design matrix
X =
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
1 0 … 0 1
⋮ ⋮
1 0 … 0 0
0 1 … 0 1
⋮ ⋮
0 1 … 0 0
⋮ ⋮
0 0 … 1 1
⋮ ⋮
0 0 … 1 0
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
.
The first I columns indicate (exclusive) membership in study i = 1, … , I and the (I + 1)th indicates treatment
assignments. For a one-stage analysis, V̂ar(𝛽) is the (I+ 1)th diagonal element of ?̂?2(X ′X)−1. First, (X′X) is (I+ 1) × (I+ 1):
X ′X =
⎛⎜⎜⎜⎝
n1 0 … n1∕2
0 n2 n2∕2
⋮ ⋱ ⋮
n1∕2 n2∕2 …
∑ni∕2
⎞⎟⎟⎟⎠ .
The inverse is
(X ′X)−1 =
⎛⎜⎜⎜⎝
… −2∕∑ni
−2∕∑ni
⋮ ⋱ ⋮
−2∕∑ni −2∕∑ni … 4∕∑ni
⎞⎟⎟⎟⎠ .
We are interested in the last element (variance of the treatment effect), which is V̂ar(𝛽) = 4𝜎
2∑ni .
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The shared-𝜎2 assumption can be relaxed in the following way: Construct a ∑ni × ∑ni diagonal matrix of weights
W, where the nonzero elements are 1∕?̂?2i ; the variance–covariance matrix is then estimated as (X
′WX)−1?̂?2. The matrix
X′WX is
The solid lines showhow thematrix can be partitioned to invert the (I+1)th diagonal element (variance of the treatment
effect), which is (∑ ni
4𝜎2i
)−1
.
This is identical to the standard inverse-variance formula used by a two-stage procedure. The algebra can also beworked
through for the estimator of 𝛽 to include weights W, that is (X′WX)−1X′Wy. The one- and two-stage procedures then
give identical results for 𝛽. This complements the result described and worked through in Senn,15 taken from Olkin and
Sampson,5 which shows that a two-stage procedure can obtain one-stage estimates when modified to make the same
assumptions of equal 𝜎2i ∀i.
A.2 Expected value of standard two-stage variance estimator
Let i = 1, … , I index studies and j = 1, … ,ni index individuals. The unadjusted estimator of 𝛽 for active vs control is
𝛽i =
2
ni
∑
actv.
𝑦𝑗 −
2
ni
∑
cont.
𝑦𝑗
with variance for study i estimated by
V̂ar(𝛽i) =
4?̂?2i
ni
.
This first stage is repeated within each study. Define weights ŵi = n∕4?̂?2i and let
Ŵ =
I∑
i=1
ŵi.
For the second stage, the inverse-variance estimator of the overall treatment effect is
𝛽 =
∑ ŵi𝛽i
Ŵ
. (A1)
The variance of 𝛽 is almost always estimated by
V̂ar(𝛽) = 1
Ŵ
=
I∑
i=1
4?̂?2i
ni
. (A2)
We now calculate the expectation of V̂ar(𝛽) for 2 studies. Note that
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?̂?2i ∼
𝜒2ni−2
𝜎2i
ni − 2
,
so E[?̂?2i ] = 𝜎
2
i ,
and Var(?̂?2i ) =
2𝜎4i
ni − 1
.
Write ?̂?2i ∼ 𝜎
2
i + 𝜀i,
where 𝜀i ∼
(
0,
2𝜎4i
ni − 1
)
.
(A3)
For a meta-analysis of two studies, our variance estimator is
V̂ar(𝛽) = 4(n1?̂?−21 + n2?̂?−22 )
−1.
Substituting x = ?̂?21 , 𝑦 = ?̂?22 , write V̂ar(𝛽) as
𝑓 (x, 𝑦) = 4(n1x−1 + n2𝑦−1)−1.
The first and second partial derivatives for x and y are
𝜕𝑓
𝜕x = n1x
−2𝑓 2,
𝜕𝑓
𝜕𝑦
= n2𝑦−2𝑓 2,
𝜕2𝑓
𝜕x2
= −2n1x−3𝑓 2 + 2n21x−4𝑓 3,
𝜕2𝑓
𝜕𝑦2
= −2n2𝑦−3𝑓 2 + 2n22𝑦
−4𝑓 3.
Denote fx after evaluating
𝜕𝑓
𝜕x at 𝜇x = 𝜎
2
1 , 𝜇𝑦 = 𝜎
2
𝑦 , and similarly for fy, fxx, fyy. By a Taylor expansion,
𝑓 (x, 𝑦) ≃𝑓 (𝜇x, 𝜇𝑦) + (𝜀x, 𝜀𝑦)
(
𝑓x
𝑓𝑦
)
+ 12 (𝜀x, 𝜀𝑦)
(
𝑓xx 𝑓x𝑦
𝑓x𝑦 𝑓𝑦𝑦
)(
𝜀x
𝜀𝑦
)
=𝑓 (𝜇x, 𝜇𝑦) + 𝜀x𝑓x + 𝜀𝑦𝑓𝑦 +
1
2
(
𝜀2x𝑓xx + 2𝜀x𝜀𝑦𝑓x𝑦 + 𝜀2𝑦𝑓𝑦𝑦
)
.
Note that E[𝜀x] = E[𝜀y] = 0, and studies are uncorrelated, so E[𝜀x𝜀y] = 0, then
E[Var(𝛽)] ≃ 𝑓 (𝜇x, 𝜇𝑦) +
1
2 (E[𝜀
2
x]𝑓xx) +
1
2 (E[𝜀
2
𝑦]𝑓𝑦𝑦). (A4)
Within each study,
E[𝜀2i ] =
2𝜎4i
ni − 1
.
Generalising to I studies,
𝑓 (x1, … , xI) = 4(n1x−11 + … + nIx−1I )
−1
𝑓xixi = 2(nix
−4
i 𝑓
3 − nix−3i 𝑓
2).
This gives us that
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E[V̂ar(𝛽)] ≃ 𝑓 (𝜎21 , … , 𝜎2I ) +
1
2
I∑
i=1
E[𝜀2i ]𝑓𝜎2i ,𝜎2i
= 4
( I∑
i=1
ni𝜎−2i
)−1
+ 12
I∑
i=1
(
2𝜎2i
ni − 1
𝑓𝜎2i 𝜎
2
i
)
.
(A5)
This result is used to compare the expectation of (A2) to the OLS fixed-effect estimator (results given in Figure 1, upper
panel).
A.3 An improved variance estimator to partner the inverse-variance estimator of ?̂?
Because the standard variance formula given in (A2) is biased downwards in finite samples, we derive an improved
estimator for the variance of (A1). Let
𝛽 = 𝑓 (𝛽1, ?̂?1, … , 𝛽I , ?̂?I) =
∑ ŵi𝛽i
Ŵ
.
First derivatives wrt 𝛽i and ŵi are
𝜕𝑓
𝜕ŵi
= 𝛽i
Ŵ
− 𝛽
Ŵ
,
𝜕𝑓
𝜕𝛽i
= ŵi
Ŵ
.
By a Taylor expansion of f(), we get
Var(𝛽) ≃
(
𝜕𝑓
𝜕𝛽1
,
𝜕𝑓
𝜕ŵ1
, … , 𝜕𝑓
𝜕𝛽I
,
𝜕𝑓
𝜕ŵI
)
×
⎛⎜⎜⎜⎜⎜⎜⎜⎝
4?̂?21
n1
0 … 0 0
0 2?̂?
4
1
n1−1
0 0
⋮ ⋱ ⋮
0 0 4?̂?
2
I
nI
0
0 0 … 0 2?̂?
4
I
nI−1
⎞⎟⎟⎟⎟⎟⎟⎟⎠
×
⎛⎜⎜⎜⎜⎜⎜⎝
𝜕𝑓
𝜕𝛽1
𝜕𝑓
𝜕ŵ1
⋮
𝜕𝑓
𝜕𝛽I
𝜕𝑓
𝜕ŵI
⎞⎟⎟⎟⎟⎟⎟⎠
(A6)
=
∑ 1
ŵi
(
ŵi
ŵ
)2
+
∑ 24σi
ni − 1
(
𝛽i − 𝛽
Ŵ
)2
= 1
Ŵ
+
2∑
i=1
2𝜎4i
ni − 1
(
𝛽i − 𝛽
Ŵ
)2
.
(A7)
The bold 0s in (A6) are always equal to 0 in meta-analysis provided studies can be assumed independent. The roman 0s
are set to 0 here because we are considering linear models, where an estimate and its variance are independent. Note that
when 𝛽 i and Var(𝛽 i) cannot be assumed independent, as with binary outcomes, the roman 0s in (A6) need to be replaced
with the correct terms.
(A7) provides a variance estimator for Gaussian data which improves on (A2) in finite samples.
A.4 Expected value of the variance estimator (A7)
The estimator is given by A1, where
ŵi =
ni
4?̂?2i
∼ niviXi
4𝜎2i
for X−1i ∼ 𝜒
2
vi ,
and 𝛽i ∼ N
(
𝛽;
4𝜎2i
ni
)
.
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𝛽i and ŵi are assumed to be independent. Note that ŵi can be expressed as a function of the random variable Xi. Let X
represent the set of all Xis.
We want the variance of 𝛽.
Var(𝛽) = EX
{
Var(𝛽|X)} + VarX {E(𝛽i)|X)}
= EX
⎧⎪⎨⎪⎩
ŵ2i
4𝜎2i
ni(∑ ŵi)2
⎫⎪⎬⎪⎭ + VarX (𝛽)
= EX
{A
B
}
,
forA =
∑
eiX2i
and B =
(∑
𝑓iXi
)2
,
where ei =
niv2i
4𝜎2i
and 𝑓i =
nivi
4𝜎2i
= eivi
.
The generic problem is that we want the expectation of the ratio
R = AB
for A and B as defined above with arbitrary positive constants ei and fi.
Use the second-order expression30
E(R) ≃ E(A)E(B) −
Cov(A,B)
E(B)2
+ Var(B)E(A)
E(B)3
. (A8)
The calculation of the required moments follows.
E(A) =
∑
i
ei
(vi − 2)(vi − 4)
,
E(B) = EX
⎧⎪⎨⎪⎩
(∑
i
𝑓iXi
)2⎫⎪⎬⎪⎭
= E
(∑
i
∑
𝑗
𝑓i𝑓𝑗XiX𝑗
)
=
∑
i
𝑓 2i E(X
2
i ) +
∑
i≠
∑
𝑗
𝑓i𝑓𝑗E(Xi)E(X𝑗)
=
∑
i
𝑓 2i
(vi − 2)(vi − 4)
+
∑
i≠
∑
𝑗
𝑓i𝑓𝑗
1
(vi − 2)(v𝑗 − 2)
,
Cov(A,B) = Cov
{∑
eiX2i ,
(∑
𝑓iXi
)2}
=
∑
i
∑
𝑗
∑
k
ei𝑓𝑗𝑓kCov(X2i ,X𝑗Xk)
=
∑
i
ei𝑓 2i Var(X
2
i ) +
∑
i≠
∑
𝑗
2ei𝑓i𝑓𝑗Cov(X2i ,XiX𝑗),
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and Var(X2i ) =
8(vi − 5)
(vi − 2)2(vi − 4)2(vi − 6)(v𝑗 − 2)
,
Cov(X2i ,XiX𝑗) =
4
(vi − 2)2(vi − 4)(vi − 6)(v𝑗 − 2)
,
E(B2) = E
⎧⎪⎨⎪⎩
(∑
i
𝑓iXi
)4⎫⎪⎬⎪⎭
= E
(∑
i
∑
𝑗
∑
k
∑
l
𝑓i𝑓𝑗𝑓k𝑓lXiX𝑗XkXl
)
=
∑
i
𝑓 4i E(X
4
i ) + 4
∑
i≠
∑
𝑗
𝑓 3i 𝑓𝑗E(X
3
i X𝑗)
+ 3
∑
i≠
∑
𝑗
𝑓 2i 𝑓
2
𝑗 E(X2i )E(X
2
𝑗 )
+ 6
∑
i≠
∑
𝑗≠
∑
k
𝑓 2i 𝑓𝑗𝑓kE(X
2
i )E(X𝑗)E(Xk)
+
∑
i≠
∑
𝑗≠
∑
k≠
∑
l
𝑓i𝑓𝑗𝑓k𝑓lE(Xi)E(X𝑗)E(Xk)E(Xl)
=
∑
i
𝑓 4i
1
(vi − 2)(vi − 4)(vi − 6)(vi − 8)
+ 4
∑
i≠
∑
𝑗
𝑓 3i 𝑓𝑗
1
(vi − 2)(vi − 4)(vi − 6)(v𝑗 − 2)
+ 3
∑
i≠
∑
𝑗
𝑓 2i 𝑓
2
𝑗
1
(vi − 2)(vi − 4)(v𝑗 − 2)(v𝑗 − 4)
+ 6
∑
i≠
∑
𝑗≠
∑
k
𝑓 2i 𝑓𝑗𝑓k
1
(vi − 2)(vi − 4)(v𝑗 − 2)(vk − 2)
+
∑
i≠
∑
𝑗≠
∑
k≠
∑
l
𝑓i𝑓𝑗𝑓k𝑓l
1
(vi − 2)(v𝑗 − 2)(vk − 2)(vl − 2)
.
Then, Var(B) = E(B2) − E(B)2.
Substituting the expectations E(A), E(B), Cov(A,B), andVar(B) into (A8) gives an expression for the actual variance of 𝛽.
This has been verified in simulation; the Mata code to calculate the formula and verify (A8) and its components is
provided as a supplement. Also included is the log file. This is run for 7 studies where, arbitratily, f = [1, 2, 3, 4, 5, 6, 7] and
e = [10, 5, 313 , 2.5, 2, 1
2
3 , 1
3
7 ]. We simulated the Xis from 1∕𝜒
2
vi and calculated
A =
7∑
i=1
eiX2i ,
B =
( 7∑
i=1
𝑓iXi
)2
,
and R = AB .
Weprovide 2 simulation results. First, Var(R) is estimated empirically from the simulated values; second, it is calculated
using (A8) where empirical values of E(A), E(B), Var(B), and Cov(A,B) are substituted for the theoretical expectations.
These results, and those based on the expectations, are given in Table A1 for 1 × 1010 repetitions. A tiny error in the
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TABLE A1 Simulation-based check of variance formula (1 × 1010 repetitions)
Empirical Approximate empirical, Theoretical
based on (A8) based on (A8)
E(A) … 0.02695 0.02695
E(B) … 1.17552 1.17554
Var(B) … 0.11525 0.11523
Cov(AB) … 0.00157 0.00157
Var(A∕B) 0.023618 0.023706 0.023704
Ratio vs empirical 1 1.00374 1.00364
approximation (A8) is seen, but the empirical and theoretical components of (A8) are near identical. This justifies the use
of the theoretical formula to compare expected variances of the inverse-variance and OLS estimators (as in Figure 1).
APPENDIX B: KENWARD–ROGER CORRECTION FOR TWO-STAGE RANDOM-EFFECTS META-
ANALYSIS ESTIMATED BY REML
This section derives the Kenward–Roger variance estimator and degrees of freedom for two-stage meta-analysis using
the notation of Kenward and Roger.19,31 We first recap the general approach and notation before applying it to the
meta-analysis model.
The general linear mixed-effects model can be written as
y = X𝜷 + Z𝜸 + e,
where y is a (k×1) vector of random variables,X is a (k×p)matrix of known constants for the (p×1) fixed-effect parameter
vector 𝜷, Z is the (k×q) design matrix for the (q×1) random-effects parameter vector 𝜸, and e is a (k×1) vector of random
error terms.
We assume E[𝜸] = 0, E[e] = 0, and Cov[𝜸, e] = 0. Define D as the (q × q) covariance matrix of the random-effects
parameters in 𝜸, andR as the (k×k) covariancematrix of e. Then,𝚺, the (k×k) covariancematrix of y, is equal toZDZ⊤+R.
After assuming normality of the random terms in the model, we obtainy ∼ N(X𝜷,𝚺).
Kenward and Roger describe 𝚺 under the general linear mixed-effects model as being an unknown, block diagonal,
(k×k) variance-covariance matrix whose elements are well-behaved functions of 𝝈(r×1).19 The standard approach would
be to use REML to find an estimate 𝝈 for 𝝈 and proceed to find a REML estimator ?̂? = 𝚽(𝝈)X⊤𝚺(𝝈)−1Y for 𝜷, with
variance ?̂?(𝝈) = [X⊤𝚺(𝝈)−1X]−1, where 𝚺 and hence𝚽 are dependent on 𝝈.
The standard REML estimator of Var(?̂?), ?̂? = [X⊤𝚺−1X]−1, is the variance-covariancematrix of the asymptotic limiting
distribution of 𝜷 based on the REML estimation of 𝝈. Kenward and Roger obtain a better approximation than ?̂? to the
finite-sample variance-covariance matrix of ?̂?.
The corrected estimator can be written as
?̂?A = ?̂? + 2?̂?
{ r∑
i=1
r∑
𝑗=1
Wi𝑗
(
Qi𝑗 − Pi?̂?P𝑗 −
1
4Ri𝑗
)}
?̂? − 14
r∑
s,t=1
WstVt?̂?Ps?̂?,
where
Pi = X⊤ 𝜕𝚺
−1
𝜕𝜎i
X ,
Qi𝑗 = X⊤
𝜕𝚺−1
𝜕𝜎i
𝚺𝜕𝚺
−1
𝜕𝜎𝑗
X ,
Ri𝑗 = X⊤𝚺−1 𝜕
2𝚺
𝜕𝜎i𝜕𝜎𝑗
𝚺−1X ,
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andWij is the (i, j)th element of the variance-covariance matrix of 𝝈, that is, ofW = Var[𝝈], which may be approximated
by the inverse of the observed or expected information matrix. Kenward and Roger give the following expression for the
expected information:
(𝝈)i𝑗 =
1
2tr
(
𝜕𝚺−1
𝜕𝜎i
𝚺𝜕𝚺
−1
𝜕𝜎𝑗
𝚺
)
− 12tr
(
2?̂?Qi𝑗 − ?̂?Pi?̂?P𝑗
)
.
The third term of ?̂?A, and therefore Vi and Sij, may be ignored if the covariance matrix 𝚺 is linear in 𝝈. Those quantities
are defined as follows:
Vi = tr
{
S 𝜕𝚺
𝜕𝜎i
}
− 2tr
{(
X⊤𝚺−1 𝜕𝚺
𝜕𝜎i
SX
)
?̂?
}
+ tr
{(
X⊤SX
)
?̂?
(
X⊤𝚺−1 𝜕𝚺
𝜕𝜎i
𝚺−1X
)
?̂?
}
,
Si𝑗 = 𝚺−1
( r∑
i,𝑗=1
Wi𝑗
𝜕2𝚺
𝜕𝜎i𝜕𝜎𝑗
)
𝚺−1.
B.1 The random-effects meta-analysis model
For the random-effects meta-analysis model, y consists of the I treatment effect estimates 𝛽 i, X = 1i, 𝜷 includes the
“pooled” effect size 𝛽, and 𝚺 is diagonal with elements 𝚺ii = ?̂?2i + 𝜏
2, where ?̂?2i is the estimated variance of 𝛽 i and 𝜏
2 is the
estimated between-study heterogeneity.
We proceed by noting that Kenward and Roger's 𝜎1 = 𝜏2(note that this is distinct from 𝜎i, the within-study standard
deviation) and also define wi =
(
𝜎2i + 𝜎1
)−1, so that 𝚺ii = w−1i . Then,
V̂ar(𝛽) = ?̂? = 1∑
iwi
,(
𝜕𝚺−1
𝜕𝜎1
)
ii
= −w2i ,
P1 = −
∑
i
w2i ,
Q11 =
∑
i
w3i .
Note that 𝚺 is linear in 𝜎1, so that 𝜕
2𝚺
𝜕𝜎21
= 𝟎. This immediately implies that R11 = 0 and also that the entire third term of
the above expression for ?̂?A is 0.
Then,
Q11 − P1?̂?P1 =
∑
i
w3i −
(∑
iw2i
)2∑
iwi
⇒ ?̂?A =
1∑
iwi
+ 2W11
(
∑
iwi)2
[∑
i
w3i −
(∑
iw2i
)2∑
iwi
]
= 1∑
iwi
⎧⎪⎨⎪⎩1 + 2W11
⎛⎜⎜⎝
∑
iw3i∑
iwi
−
[∑
iw2i∑
iwi
]2⎞⎟⎟⎠
⎫⎪⎬⎪⎭ ,
whereW11 = Var[𝜎1] as explained earlier.
The expected information works out to be
E(?̂?1) =
1
2
∑
i
w2i −
∑
iw3i∑
iwi
+ 12
[∑
iw2i∑
iwi
]2
.
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If we wish to use the observed information, this requires the second derivative of the log-likelihood with respect to 𝜎1.
log(𝜎1) = constant +
1
2
∑
i
log(wi) −
1
2 log
∑
i
wi −
1
2
∑
i
wi(𝛽i − 𝛽)2
Note that 𝛽 is itself a function of 𝜎1 and must also be differentiated. Concentrating first on this term, let vi = 𝛽i − 𝛽 so that
the final term becomes − 12
∑
iwiv2i . Then,
−12
𝜕
𝜕𝜎1
∑
i
wiv2i = −
∑
i
wiviv′i −
1
2
∑
i
w′iv
2
i .
Now, using the quotient rule and rearranging,
v′i =
𝜕
𝜕𝜎1
∑wi𝛽i∑wi = −
∑
iw2i vi∑
iwi
∀i
⇒ −
∑
i
wiviv′i =
∑
iw2i vi∑
iwi
∑
i
wivi.
But
∑
i
wivi =
∑
i
wi𝛽i −
∑
i
wi
∑
iwi𝛽i∑
iwi
= 0
⇒ −12
𝜕
𝜕𝜎1
∑
i
wiv2i = −
1
2
∑
i
w′iv
2
i =
1
2
∑
i
w2i v
2
i
⇒ −12
𝜕2
𝜕𝜎21
∑
i
wiv2i = −
(
∑
iw2i vi)
2∑
iwi
−
∑ 3
w
i
v2i by the product rule.
Now, we go back and calculate the second differentials of the first two (non-constant) terms:
1
2
𝜕2
𝜕𝜎21
∑
i
log(wi) =
1
2
∑
i
w2i ,
−12
𝜕2
𝜕𝜎21
log
∑
i
wi =
1
2
[∑
iw2i∑
iwi
]2
−
∑
iw3i∑
iwi
.
Hence, the expression for observed information is
O(𝜎1) = −
𝜕2
𝜕𝜎21
log(𝜎1) =
[∑
iw2i (𝛽i − 𝛽)
]2∑
iwi
+
∑
w3i (𝛽i − 𝛽)
2 − E(𝜏2).
Finally,
V̂ar(𝛽) = ?̂?A =
1∑
iwi
⎧⎪⎪⎨⎪⎪⎩
1 +
2
(∑
iw3i∑
iwi
−
[∑
iw2i∑
iwi
]2)
(𝜎1)
⎫⎪⎪⎬⎪⎪⎭
,
where (𝜎1)may be either E(𝜎1) or O(𝜎1).
Kenward andRoger consider inferences of the formL𝜷 forL a fixed (l × p)matrix, where l is the number of simultaneous
inferences and p is the number of elements of 𝜷. Here, l = p = 1(since we simply wish to estimate 𝛽), hence L = 1 also.
Furthermore, since l = 1, the test distribution is t rather than F, and the scaling factor 𝜆 should also be equal to 1.
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To calculate approximate degrees of freedomm, working through the formulae of Kenward and Roger19(p987):
A1 =
∑
i
∑
𝑗
Wi𝑗tr (𝚯𝚽Pi𝚽) tr
(
𝚯𝚽P𝑗𝚽
)
,
A2 =
∑
i
∑
𝑗
Wi𝑗tr
(
𝚯𝚽Pi𝚽𝚯𝚽P𝑗𝚽
)
,
Θ = L
(
L⊤𝚽L
)−1L⊤ = 𝚽−1,
⇒ A1 = A2 = W11P21?̂?2A
g = (l + 1)A1 − (l + 4)A2
(l + 2)A2
= 2A1 − 5A13A1
= −1,
⇒ 3l + 2 (1 − g) = 7⇒ c1 =
g
3l + 2 (1 − g) = −
1
7 ,
c2 =
l − g
3l + 2 (1 − g) =
2
7 ,
and c3 =
l + 2 − g
3l + 2 (1 − g) =
4
7 .
Next,
E[F] =
(
1 − A2l
)−1
= (1 − A1)−1,
B = 12l (A1 + 6A2) =
7
2A1,
and
V[F] = 2l
{
1 + c1B
(1 − c2B)2 (1 − c3B)
}
= 2 − A1
(1 − A1)2 (1 − 2A1)
⇒ 𝜌 = V[F]
2E[F]2
=
1 − 12A1
1 − 2A1
,
⇒ m = 4 + l + 2l𝜌 − 1 =
2
A1
= 2
W11P21?̂?2A
,
and 𝜆 = mE[F] (m − 2) = 1.
IfW11 is based on the observed information matrix, the degrees of freedom are
mO =
2
[∑
iw2i (𝛽i−𝛽)
]2∑
iwi
+ 2∑iw3i (𝛽i − 𝛽)2 −∑iw2i + 2∑iw3i∑iwi − [∑iw2i∑iwi ]2
?̂?2A
(∑
iw2i
)2
or if based on the expected information matrix:
mE =
∑
iw2i − 2
∑
iw3i∑
iwi
+
[∑
iw2i∑
iwi
]2
?̂?2A
(∑
iw2i
)2 .
